March 12, 2019

Grassley, Wyden Invite 5 Pharmacy Benefit Managers to Drug Pricing Hearing

WASHINGTON
– U.S. Senate Finance Committee Chairman Chuck Grassley of Iowa and Ranking
Member Ron Wyden of Oregon today invited executives from five pharmacy benefit
manager (PBMs) companies to testify before a committee hearing on Wednesday,
April 3, 2019, on drug pricing in the United States, the third in a series of
hearings examining prescription drug costs.
 
The
companies invited include Cigna Corporation, CVS Caremark and CVS Health
Corporation, Humana Inc., OptumRx and Prime Therapeutics LLC.
 
“Middlemen
in the health care industry owe patients and taxpayers an explanation of their
role. There’s far too much bureaucracy and too little transparency getting in
the way of affordable, quality health care,” Grassley and Wyden said. “We’ve
heard from pharmaceutical companies and it’s only fair that the committee has
the opportunity to ask questions of other players in the health care supply
chain. Every part of the industry has a role to play in lowering prescription
drug prices. Witnesses from these companies should come prepared to provide
real information and discuss real solutions.”
 
The
Finance Committee held its first
hearing
on drug pricing on January 29 and its second
hearing
on drug pricing on February 26.
 
Links
to the letters inviting the companies to testify can be found below.
 

Print 
Email 
Share 
Share